Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Corcept Therapeutics (CORT)

Corcept Q3 revenue rises 64% to $340.5 million; 2026 revenue guidance reiterated

Positive Impact 3 of 5 earnings

Corcept Therapeutics reported third quarter 2026 revenue of $340.5 million, up 64 percent from the same period in 2025, and net income of $126.8 million, compared with $19.7 million a year earlier. The company reiterated its 2026 revenue guidance of $1.1 billion to $1.2 billion, and its Lifyorli ovarian cancer product contributed $91.4 million of the quarter's revenue.

Key points

  • Q3 2026 revenue of $340.5 million vs. $207.6 million in Q3 2025; Korlym and authorized generic revenue was $249.1 million and Lifyorli revenue was $91.4 million
  • Q3 2026 net income of $126.8 million, or $1.01 per diluted share, vs. $19.7 million, or $0.16 per diluted share, in Q3 2025
  • 2026 revenue guidance of $1.1 billion to $1.2 billion reiterated; cash and investments rose to $662.3 million at September 30, 2026
  • Relacorilant for Cushing's syndrome has a PDUFA date of December 17, 2026

The filing

CompanyCorcept Therapeutics (CORT)
Form8-K, current report
Filed with the SECNov 3, 2026, 4:09 PM ET
Accession number0001628280-26-069494

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 7, 2026, 11:17 PM ET, from the text of the filing and its press-release exhibits only.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.